# Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test

> **NCT03864978** · PHASE2 · UNKNOWN · sponsor: **Alfasigma S.p.A.** · enrollment: 236 (estimated)

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** Rifaximin delayed release 400 mg tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03864978
- **Lead sponsor:** Alfasigma S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-22
- **Primary completion:** 2020-04
- **Final completion:** 2020-10
- **Target enrollment:** 236 (ESTIMATED)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864978, "Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath Test". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03864978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*